Improving patient & practice outcomes in depression care.
Do you find that many of your MDD patients fail to respond to SSRIs?
Are your patients struggling through months of failed treatments due to the educated guessing that applies to the current standard of care for MDD?
Watch our on-demand webinar with
Dr. Nikolaos Mellios, our Chief Scientific Officer, to learn about MindLight Antidepressant Response Test™, the first truly predictive antidepressant response test based on circular RNA biomarkers. MindLight™ analyzes a brain-derived circular RNA biomarker that predicts whether an adult MDD patient will respond to SSRI therapy. The MindLight test predicts SSRI response with high accuracy, and this precision test will streamline the treatment process for your MDD patients.
What you'll learn about:
Circular RNAs as novel, brain-derived biomarkers with key attributes in precision psychiatry
The biology behind the biomarker analyzed by MindLight and its role in the known antidepressant response pathways (serotonin and BDNF)
How MindLight stratifies MDD patients identifying those patients that have a low likelihood of response to SSRIs
The clinical utility and benefits of the MindLight™ test in treatment planning for major depressive disorder
How MindLight will elevate the quality of care for your MDD patients
